scispace - formally typeset
E

Erwin W. Gelfand

Researcher at University of Colorado Denver

Publications -  679
Citations -  37565

Erwin W. Gelfand is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Immunoglobulin E & T cell. The author has an hindex of 99, co-authored 675 publications receiving 36059 citations. Previous affiliations of Erwin W. Gelfand include University of Colorado Hospital & University of Virginia.

Papers
More filters
Journal ArticleDOI

Personal monitoring of respirable endotoxin and the consequences of furry animal exposure in asthmatic schoolchildren

Steven J. Dutton, +5 more
- 01 Jan 2002 - 
Journal ArticleDOI

Future directions of immunoglobulin therapy: Foreword

Mark Ballow, +4 more
- 01 Nov 1990 - 
TL;DR: This symposium has taken a new direction in reviewing the potential therapeutic role of monoclonal antibodies in the treatment of malignancy and autoimmune diseases by reviewing the history and current state of hybridoma technology.
Journal Article

Transplantation in severe combined immunodeficiency disease with hl-a identical bone marrow.

Erwin W. Gelfand, +2 more
- 01 Jan 1975 - 
TL;DR: The immunologic reconstitution of 7 patients with severe combined immunodeficiency disease was attempted with bone marrow transplantation from histoidentical donors and four patients were successfully reconstituted and discharged from the hospital.
Journal ArticleDOI

Therapeutic benefits of recombinant alpha1-antitrypsin IgG1 Fc-fusion protein in experimental emphysema.

Katsuyuki Takeda, +4 more
- 09 Feb 2021 - 
TL;DR: Compared to pAAT, AAT-Fc more effectively prevented or attenuated elastase- andCS-induced models of emphysema and may provide a therapeutic option to individuals with AATD- and CS-induced emphySEma.
Journal ArticleDOI

CFTR-mediated monocyte/macrophage dysfunction revealed by cystic fibrosis proband-parent comparisons

Xi Zhang, +14 more
- 22 Mar 2022 - 
TL;DR: Insight is provided into demonstrated CFTR-related innate immune dysfunction in individuals with CF and carriers of a CFTR mutation that may serve as a target for personalized therapy.